Página principal > Artículos > Artículos publicados > Resultados de la búsqueda: 2152-2669_a2018v18n12

Artículos publicados

  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Artículos publicados Encontrados 1 registros  La búsqueda tardó 0.01 segundos. 
1.
19 p, 600.4 KB Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma / Barrientos, Jacqueline C. (Zucker School of Medicine at Hofstra/Northwell) ; O'Brien, Susan (University of California Irvine) ; Brown, Jennifer R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Kay, Neil E. (Mayo Clinic) ; Reddy, Nishitha M. (Vanderbilt-Ingram Cancer Center) ; Coutre, Steven E (Stanford University School of Medicine) ; Tam, Constantine (Peter MacCallum Cancer Centre and St Vincent's Hospital) ; Mulligan, Stephen (Royal North Shore Hospital) ; Jaeger, Ulrich (Medical University of Vienna) ; Devereux, Stephen (King's College Hospital NHS Foundation Trust) ; Pocock, Christopher (East Kent Hospitals University) ; Robak, Tadeusz (Medical University of Lodz) ; Schuster, Stephen J. (Perelman Center for Advanced Medicine) ; Schuh, Anna (University of Oxford) ; Gill, Devinder (Princess Alexandra Hospital) ; Bloor, Adrian (The Christie Clinic) ; Dearden, Claire (The Royal Marsden Hospital) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Cull, Gavin (Sir Charles Gardiner Hospital) ; Hamblin, Mike (Colchester Hospital) ; Jones, Jeffrey A. (The Ohio State University Comprehensive Cancer Center) ; Eckert, Karl (Pharmacyclics LLC. an AbbVie Company) ; Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company) ; Suzuki, Samuel (Pharmacyclics LLC. an AbbVie Company) ; Hsu, Emily (Pharmacyclics LLC. an AbbVie Company) ; James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ; Byrd, John C. (The Ohio State University Comprehensive Cancer Center) ; Hillmen, Peter (The Leeds Teaching Hospitals. St. James University Hospital) ; Universitat Autònoma de Barcelona
In the phase III study RESONATE, ibrutinib reduced the risk of progression and improved overall survival versus ofatumumab in previously treated patients with CLL/SLL. In this novel analysis of patient well-being including patient-reported outcomes, ibrutinib reduced disease burden while preserving parameters of hematologic and immunologic function in RESONATE. [...]
2018 - 10.1016/j.clml.2018.08.007
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18 Núm. 12 (december 2018) , p. 803-813.e7  
Registro completo - Creative Commons

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos